国: アイルランド
言語: 英語
ソース: HPRA (Health Products Regulatory Authority)
PARICALCITOL
Abbott Laboratories Ireland Ltd
4 Microgram
Capsules, Soft
2008-01-25
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zemplar 4 micrograms capsules, soft 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule, soft contains For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsule, soft Oval, gold soft capsule imprinted with and ZK 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease Stages 3 and 4) patients and chronic renal failure (chronic kidney disease Stage 5) patients on haemodialysis or peritoneal dialysis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Zemplar can be taken with or without food. CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 Zemplar should be administered once a day, either daily or three times a week taken every other day. INITIAL DOSE The initial dose is based on baseline intact parathyroid hormone (iPTH) levels. DOSE TITRATION Dosing must be individualised based on serum or plasma iPTH levels, with monitoring of serum calcium and serum phosphorus. Table 2 presents a suggested approach for dose titration. Paricalcitol Excipients (Ethanol) Zemplar 4 micrograms 4 micrograms 1.42 mg TABLE 1. INITIAL DOSE BASELINE IPTH LEVEL DAILY DOSE THREE TIMES A WEEK DOSE * ≤ 500 pg/mL (56 pmol/L) 1 microgram 2 micrograms > 500 pg/mL (56 pmol/L) 2 micrograms 4 micrograms * To be administered no more frequently than every other day IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 21/07/2011_ _CRN 2090909_ _page number: 1_ Serum calcium levels should be closely monitored after initiation of the treatment and during dose titration periods. If hypercalcemia or a persistently elevated 完全なドキュメントを読む